| scholarly article | Q13442814 |
| P2093 | author name string | Georg Hess | |
| Kurt W Schmid | |||
| Martin Schuler | |||
| Florian Grabellus | |||
| Claudia Stolz | |||
| Patricia S Hähnel | |||
| Sandra Hoffarth | |||
| P2860 | cites work | Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis | Q40147477 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | B-cell lymphoma | Q4833719 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 3312-3321 | |
| P577 | publication date | 2008-08-08 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis | |
| P478 | volume | 112 |
| Q21129306 | ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma |
| Q37601775 | Anti-CD20 monoclonal antibodies: historical and future perspectives |
| Q38820373 | Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates. |
| Q37605247 | Antibody-based therapy of leukaemia |
| Q37022297 | Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells |
| Q92965138 | BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines |
| Q38682214 | Brucea javanica oil emulsion alleviates cachexia induced by Lewis lung cancer cells in mice. |
| Q35919697 | Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics |
| Q39192585 | Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties |
| Q39608912 | Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement |
| Q52682181 | Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas. |
| Q39002036 | Emerging biological therapies to treat acute lymphoblastic leukemia |
| Q39407871 | Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. |
| Q37676785 | Evolution of anti-CD20 monoclonal antibody therapeutics in oncology |
| Q36292012 | Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity |
| Q60907666 | Identification of TRA-1-60-positive cells as a potent refractory population in follicular lymphomas |
| Q35237511 | Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? |
| Q38152651 | Impact of rituximab trials on the treatment of ANCA-associated vasculitis |
| Q92005612 | Improvement of the rituximab-induced cell death by potentiation of the store-operated calcium entry in mantle cell lymphoma cell lines |
| Q42707894 | Increased 8-hydroxy-2'-deoxyguanosine in plasma and decreased mRNA expression of human 8-oxoguanine DNA glycosylase 1, anti-oxidant enzymes, mitochondrial biogenesis-related proteins and glycolytic enzymes in leucocytes in patients with systemic lup |
| Q37351043 | Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival |
| Q38066195 | Mechanisms of action of CD20 antibodies |
| Q35098110 | MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. |
| Q41233808 | Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy |
| Q37448352 | Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention |
| Q37613872 | Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia |
| Q36619787 | Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo |
| Q64883255 | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. |
| Q28484381 | Parametric model of combination therapy for Non-Hodgkin Lymphoma |
| Q37653639 | Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma |
| Q37735840 | Plerixafor: a peripheral blood stem cell mobilizer |
| Q30406180 | Primary bladder lymphoma, diffuse large B-cell type: Case report and literature review of 26 cases |
| Q24607358 | Rituximab: mechanism of action |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q28390097 | SIRT3 and cancer: tumor promoter or suppressor? |
| Q38914858 | Survival control of malignant lymphocytes by anti-apoptotic MCL-1. |
| Q35599741 | Targeted treatment for chronic lymphocytic leukemia |
| Q39710538 | Targeting neural-restrictive silencer factor sensitizes tumor cells to antibody-based cancer immunotherapy in vitro via multiple mechanisms |
| Q37634558 | Targeting the BCL-2 family in malignancies of germinal centre origin. |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q38577849 | The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies |
| Q37178611 | Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies |
| Q37672125 | Understanding and circumventing resistance to anticancer monoclonal antibodies. |
| Q37431491 | Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics |
| Q33406478 | Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis |
Search more.